What medications should be offered for an adult patient with emphysema?

Medication Management for Emphysema

For an adult patient with emphysema, initiate treatment with a long-acting bronchodilator (either a long-acting muscarinic antagonist [LAMA] or long-acting beta-2 agonist [LABA]), escalating to combination LAMA/LABA therapy if symptoms persist, and reserve inhaled corticosteroids (ICS) only for patients with frequent exacerbations (≥2 per year) or features of asthma overlap.

Initial Bronchodilator Therapy

The foundation of emphysema treatment centers on bronchodilators, which relax airway smooth muscle and improve symptoms even when spirometric changes are minimal 1. Start with:

For Mild, Intermittent Symptoms:

• Short-acting bronchodilators (short-acting beta-2 agonist or short-acting anticholinergic) used as needed 2, 3
• Either agent is acceptable; choice depends on individual response

For Persistent Symptoms:

• Long-acting bronchodilator monotherapy as first-line 2
• LAMA or LABA are equally appropriate initial choices
• Inhaled delivery is preferred over oral routes to minimize systemic side effects 1

Escalation Strategy Based on Symptom Burden

If Symptoms Persist on Single Long-Acting Agent:

• Escalate to dual bronchodilator therapy (LAMA + LABA) 2
• This combination is more effective than either agent alone
• Continue this regimen before considering ICS addition

Critical Caveat on Inhaled Corticosteroids:

Use ICS with significant caution in emphysema patients. Unlike asthma, emphysema does not respond reliably to corticosteroids 3. Consider ICS only when:

• Patient experiences ≥2 exacerbations per year despite optimal bronchodilator therapy 2, 4
• Features suggest asthma-COPD overlap
• Blood eosinophil levels are elevated (though this requires prospective validation) 4

Important safety concern: ICS increases pneumonia risk in COPD patients 2, and recent evidence suggests increased risk of non-tuberculous mycobacterial infections, particularly in those with low body weight or alpha-1 antitrypsin deficiency 5.

Corticosteroid Trial Protocol

Before committing to long-term ICS therapy 3:

• Perform spirometry before and after 30 mg oral prednisolone daily for 2 weeks
• A positive response requires FEV1 improvement of ≥200 mL AND ≥15% from baseline
• Only 10-20% of emphysema patients show objective improvement
• Subjective improvement alone is insufficient to justify continued therapy

Additional Therapies for Frequent Exacerbators

For Patients with ≥2 Exacerbations/Year Despite Optimal Bronchodilators:

Triple therapy (LAMA + LABA + ICS) is the next step 2

Alternative or additive agents 2, 4:

• Roflumilast (phosphodiesterase-4 inhibitor): Consider if FEV1 <50% predicted with chronic bronchitis phenotype
• Azithromycin (250 mg three times weekly): For former smokers to reduce exacerbation frequency 2, 4
  • Must exclude non-tuberculous mycobacterial infection before starting
  • Monitor for hearing loss and QT prolongation
• Mucolytic agents (e.g., N-acetylcysteine): For chronic bronchitis with frequent exacerbations

Acute Exacerbation Management

During exacerbations 6, 4:

• Short-acting bronchodilators (beta-2 agonist with or without anticholinergic) via MDI with spacer or nebulizer
• Systemic corticosteroids: Prednisone 40 mg daily for 5 days (not longer) 4
• Antibiotics for 5-7 days if increased sputum purulence present 1, 4
  • First-line: Amoxicillin, doxycycline, or macrolides based on local resistance patterns
  • Reserve amoxicillin/clavulanate or fluoroquinolones for treatment failures

Essential Non-Pharmacologic Measures

• Smoking cessation is mandatory at all disease stages 1, 3
• Nicotine replacement therapy increases quit rates 1
• Influenza and pneumococcal vaccination 2
• Pulmonary rehabilitation for moderate-to-severe disease 3
• Long-term oxygen therapy if PaO2 ≤55 mmHg or oxygen saturation ≤88% at rest 3

Common Pitfalls to Avoid

1. Do not use ICS as first-line therapy in emphysema without clear indication (frequent exacerbations or asthma features)
2. Avoid theophyllines as routine therapy—limited value and significant side effect profile 3, 4
3. Do not use prophylactic antibiotics routinely (exception: azithromycin in selected frequent exacerbators) 2
4. Verify proper inhaler technique at every visit—device selection matters for patients with coordination difficulties 1, 7
5. Screen for NTM infection before starting macrolides or ICS, particularly in patients with low BMI or structural lung disease 5